COMPUGEN news, videos and press releases - Page 5
For more news please use our advanced search feature.
COMPUGEN - More news...
COMPUGEN - More news...
- Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis
- Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting
- Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities
- Compugen Reports First Quarter 2021 Results
- Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series
- Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen
- Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021
- Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting
- Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy
- Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy
- Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference
- Compugen Reports Fourth Quarter and Full Year 2020 Results
- Compugen Announces Data Update from COM701 Phase 1 Clinical Trial
- Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®
- Compugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, 2021
- Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products
- Compugen to Present at Upcoming Investor Conferences
- Compugen Reports Third Quarter 2020 Results
- Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China
- Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy
- Compugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020
- Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board
- Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
- Compugen to Present at Upcoming September 2020 Investor Conferences
- Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent
- Compugen Reports Second Quarter 2020 Results
- Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020
- Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
- Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
- Compugen Reports First Quarter 2020 Results
